Drug Trial Radar · NCT03036813
Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE)
Last checked: Nov 20, 2026Latest source record: Jul 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
449
Actual
Start
Dec 2016
Primary completion
Oct 8, 2019
Study completion Oct 8, 2019
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jan 30, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of Voxelotor Administered Orally to Patients With Sickle Cell Disease
Conditions
- Sickle Cell Disease
Interventions
voxelotorDrug
PlaceboOther
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Increase in Hb >1 g/dL From Baseline to Week 24Time frame: Baseline to Week 24
Locations
62 sites in 12 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Mobile, Alabama
Site not named
Little Rock, Arkansas
Site not named
Oakland, California
Site not named
Miami, Florida
Site not named
Atlanta, Georgia
Site not named
Chicago, Illinois
Site not named
Indianapolis, Indiana
Site not named
Baton Rouge, Louisiana
Site not named
New Orleans, Louisiana
Site not named
Baltimore, Maryland
Site not named
Bethesda, Maryland
Site not named
Boston, Massachusetts
Site not named
Boston, Massachusetts
Site not named
Detroit, Michigan
Site not named
Newark, New Jersey
Site not named
New York, New York
Site not named
The Bronx, New York
Site not named
Chapel Hill, North Carolina
Site not named
Durham, North Carolina
Site not named
Greenville, North Carolina
Site not named
Oklahoma City, Oklahoma
Site not named
Philadelphia, Pennsylvania
Site not named
Pittsburgh, Pennsylvania
Site not named
Charleston, South Carolina
Site not named
Memphis, Tennessee
Site not named
Nashville, Tennessee
Site not named
Houston, Texas
Site not named
Richmond, Virginia
Site not named
Toronto, Canada
Site not named
Alexandria, Egypt
Site not named
Cairo, Egypt
Site not named
Cairo, Egypt
Site not named
Zagazig, Egypt
Site not named
Créteil, France
Site not named
Paris, France
Site not named
Paris, France
Site not named
Padova, Italy
Site not named
Verona, Italy
Site not named
Monza, Milano, Italy
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.